Rivaroxaban 2.5 mg twice daily did not significantly reduce the composite of death, myocardial infarction, or stroke compared to placebo (HR 0.94; 95% CI 0.84-1.05; P=0.27).
RCT (n=5,022)
Double-blind
Randomized
Does rivaroxaban reduce the composite of death, myocardial infarction, or stroke in patients with worsening chronic heart failure, LVEF ≤40%, coronary artery disease, and no atrial fibrillation?
Rivaroxaban 2.5 mg twice daily does not improve clinical outcomes in patients with worsening HFrEF, coronary artery disease, and sinus rhythm.
Effect estimate: HR 0.94 (95% CI 0.84-1.05)
Absolute Event Rate: 25% vs 26.2%
p-value: p=0.27
BACKGROUND: Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease. METHODS: In this double-blind, randomized trial, 5022 patients who had chronic heart failure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation were randomly assigned to receive rivaroxaban at a dose of 2.5 mg twice daily or placebo in addition to standard care after treatment for an episode of worsening heart failure. The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke. The principal safety outcome was fatal bleeding or bleeding into a critical space with a potential for causing permanent disability. RESULTS: Over a median follow-up period of 21.1 months, the primary end point occurred in 626 (25.0%) of 2507 patients assigned to rivaroxaban and in 658 (26.2%) of 2515 patients assigned to placebo (hazard ratio, 0.94; 95% confidence interval CI, 0.84 to 1.05; P=0.27). No significant difference in all-cause mortality was noted between the rivaroxaban group and the placebo group (21.8% and 22.1%, respectively; hazard ratio, 0.98; 95% CI, 0.87 to 1.10). The principal safety outcome occurred in 18 patients who took rivaroxaban and in 23 who took placebo (hazard ratio, 0.80; 95% CI, 0.43 to 1.49; P=0.48). CONCLUSIONS: Rivaroxaban at a dose of 2.5 mg twice daily was not associated with a significantly lower rate of death, myocardial infarction, or stroke than placebo among patients with worsening chronic heart failure, reduced left ventricular ejection fraction, coronary artery disease, and no atrial fibrillation. (Funded by Janssen Research and Development; COMMANDER HF ClinicalTrials.gov number, NCT01877915 .).
Zannad et al. (Mon,) conducted a rct in Chronic heart failure and coronary artery disease (n=5,022). Rivaroxaban vs. Placebo was evaluated on Composite of death from any cause, myocardial infarction, or stroke (HR 0.94, 95% CI 0.84-1.05, p=0.27). Rivaroxaban 2.5 mg twice daily did not significantly reduce the composite of death, myocardial infarction, or stroke compared to placebo (HR 0.94; 95% CI 0.84-1.05; P=0.27).